Sep 11 • 🧠Pep Ed
DAY 8: WHY FDA DISAGREED
What was the FDA’s side of the argument?
You probably won’t hear me call the FDA a champion of peptide access very often.
But facts are facts: in the retatrutide dispute, it was Eli Lilly asking for the broader “biologic” classification—and the FDA said no.
Here’s the argument in plain English:
The FDA’s rule says a protein must contain more than 40 alpha amino acids.
Retatrutide has:
- 39 alpha amino acids in its main chain
- One additional alpha amino acid in its side chain
- One side-chain component that is not an alpha amino acid
That gives the FDA a count of 40—not more than 40.
Lilly counted all 41 components and argued that retatrutide should therefore be treated as a protein and regulated as a biologic.
The FDA’s response was essentially:
You cannot count a non-alpha component as an alpha amino acid simply to cross the line.
Why was the FDA so firm?
The agency said the 40-amino-acid cutoff was created as a bright line. A molecule either crosses that line or it doesn’t.
If manufacturers could count attached spacers and other side-chain pieces—or argue that a molecule merely behaves like a protein—the FDA believed every classification would turn into a case-by-case negotiation.
The FDA also rejected Lilly’s backup argument that retatrutide should be considered “analogous to a protein.” According to the agency, that would allow companies to work around the very definition the rule was designed to establish.
What does this mean for our community?
Let’s be clear: the FDA was not making a speech about protecting peptide freedom.
Its argument was about applying its rule consistently.
But the result still matters.
Lilly wanted retatrutide moved into the biologics framework. The FDA refused to stretch its definition to get it there. That classification can affect the approval pathway, follow-on competition and the future options available to compounders.
It does not mean retatrutide is FDA-approved or legally available for compounding today. It means the FDA classified it as a drug rather than a biologic.
The part people shouldn’t miss
A federal court later agreed that the FDA could reasonably conclude retatrutide was not technically a protein. However, the court said the FDA had not adequately explained why it also could not be considered analogous to a protein, so that portion was sent back for further consideration.
In other words, this was not a total win for either side.
My takeaway
We don’t have to trust every FDA decision to recognize what happened here:
Big Pharma asked the FDA to count the molecule in a way that would place it in the biologics lane. The FDA refused.
That doesn’t make the FDA our hero. But it does show why we must read the actual arguments instead of assuming the regulator and the manufacturer are always standing on the same side.
Because when one amino-acid classification can influence access, competition and control, the details matter.
What do you think: should classification depend strictly on the molecule’s structure—or should a manufacturer be able to argue that its product “acts like” a protein?
Educational information only. This is not medical or legal advice.
14
5 comments
DAY 8: WHY FDA DISAGREED
Leaderboard (30-day)
1
+59
2
+42
3
+17
4
+15
5
+14
Powered by